AnaptysBio had its Relative Strength (RS) Rating upgraded from 72 to 84 Thursday.
Risk Management In The Stock Market: How Much Money To Invest Now
This unique rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major indexes.
History shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating as they begin their biggest price moves.
AnaptysBio is not currently showing a potential entry point. See if the stock goes on to build a chart pattern that could kick off a new price move.
The company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 287%.
The company holds the No. 117 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
